(PharmaNewsWire.Com, June 22, 2017 ) Browse 96 market data tables and 35 figures spread through 215 pages and in-depth TOC on "Next-Generation Sequencing (NGS) Market"
Early buyers will receive 10% customization on this report.
This report studies the global next generation sequencing market over the forecast period of 2017 to 2022. The global next-generation sequencing market is estimated to grow at a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 Billion by 2022. Factors such as technological advancements in NGS platforms, increasing applications of NGS, growing partnerships and collaborations, and increasing adoption of NGS among research laboratories and academic institutes are driving the growth of this market.
On the basis of product and service, the NGS market is categorized into pre-sequencing products and services, NGS platforms, consumables, services for platforms, sequencing services, and bioinformatics. In 2017, the consumables segment is expected to account for the largest share of the market. The pre-sequencing products and services segment is expected to register the highest CAGR during the forecast period primarily due to the growing need for standardized sample preparation solutions and increasing automation in pre-sequencing.
Based on applications, the market is categorized into six segments, namely, diagnostics, drug discovery, biomarker discovery, precision medicine, agriculture & animal research, and other application. The diagnostics application segment is expected to account for the major share of the global NGS market owing to the increasing focus of key market players on providing & developing NGS-based diagnostic tests and the growing adoption of NGS-based diagnostic tests related to oncology and infectious diseases.
On the basis of technology, the global NGS market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2017, the SBS technology is expected to account for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina’s systems (including the HiSeq series and MiSeq), and the growing demand for NextSeq and HiSeq X Ten.
On the basis of end user, the market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. Among these end users, the hospitals and clinics segment is expected to register the highest CAGR due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics.
Geographically, the NGS market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to command the largest share of the market in 2017, followed by Europe. The market in North America is primarily driven by the technological advancements, availability of commercial solutions for NGS data analysis, and the strong presence of key players in this region. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, due to the improving healthcare infrastructure and favorable government initiatives in this region.
The major players in the global next-generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg).
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
